HO PHARMACOPEIAL DRUGS 



was Dr. Squibb impressed in its favor as to lead him to 

 write, (1879) : 



"It is to be hoped that the revision committee will 

 recognize it in the forthcoming issue of the U. 8. Phar- 

 macopeia. 11 



The commendations of Dr. Squibb were probably 

 instrumental in obtaining for convallaria this honor, 

 for in 1900 it obtained official recognition. 



In Russia, convallaria was investigated by the medi- 

 cal profession as early as 1880, having long before been 

 used in dropsy by the people. About 1883 it became 

 fashionable elsewhere, being generally commended as a 

 substitute for digitalis in certain specific conditions. 



A study of the chemistry of convallaria antedated 

 its use in professional medicine, for in 1858 G. F. Walz 

 published an analysis in the N. Jahrbuchf. Pharm., de- 

 scribing two "most important constituents," viz., con- 

 vallarin and convallamarin. He states that his experi- 

 ments were made long before their publication. It is 

 to be seen that the empirical use of convallaria pre- 

 vailed centuries before its employment as a remedy by 

 the licensed profession of medicine, (1883), and that 

 the chemist also anticipated its probable employment 

 in therapy. 



COPAIBA (COPAIFERA OPFICINALIS) 



(Copaiba) Copaifera Langsdorffii 



Official in every U. S. P., from 1820 to and including 1910, 

 which makes official the oleoresin derived from South American 

 species of Copaiba. 



On the spelling of the name of this drug we quote 

 from a private letter from Dr. Charles Rice (548a), 

 New York, who for several decades was Chairman of 

 the Committee on Revision of the U. S. Pharmacopeia: 



